Floatz logo

Baclofen

Myelodysplastic/Myeloproliferative Neoplasm

Alliance for Clinical Trials in OncologySmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

42 Active assets in the Myelodysplastic/Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
Etoposide
M.D. Anderson Cancer Center
Phase 3BBB
Melphalan
M.D. Anderson Cancer Center
Phase 2/3BBB
Cytarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Cyclosporin A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
Busulfanum
Jacqueline Garcia, MD
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Baclofen is also rated in:

spastic hemiplegiaDormant
BB
Indicative · Phase 4
68 / 100
View asset →
stroke disorderDormant
BB
Indicative · Phase 4
68 / 100
View asset →
cerebral palsyDormant
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →